×

SteadyMed Hires Pulmonary Hypertension Veteran to Lead Patient Advocacy and Community Relations

SAN RAMON, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has hired Carl Hicks, Jr., in a newly created role of Vice President of PH Patient Advocacy and Community Relations.

Hicks, a 20-year veteran in the fight against pulmonary hypertension (PH), is a nationally and internationally recognized advocate for patients, caregivers, and the PH community. He joins SteadyMed from the Pulmonary Hypertension Association (PHA), the world’s leading PH patient advocacy organization, where he served in a number of roles including Executive Vice President, Chairman of the Board and Board member since 2000. Carl is very well known and respected nationally and internationally by many PH physicians, patients and caregivers for his devotion to helping this community.

“We are delighted that Carl joins us in this very important role,” said Jonathan Rigby, President & CEO of SteadyMed. “His devotion to patients and the broader PH community, as well as his rich, relevant experience will be invaluable to us as we prepare to file a New Drug Application (NDA) for Trevyent®, our lead drug product candidate for the treatment of pulmonary arterial hypertension, in Q2 in 2017. SteadyMed is committed to building a strong relationship with this underserved patient population and meeting their needs in a meaningful and impactful manner.”

“I am thrilled to join SteadyMed, a company that prides itself with a strong patient focus,” said Carl Hicks, Vice President, PH Patient Advocacy and Community Relations. “The loss of my daughter to PH drives me to be a fierce advocate for this devastating disease. In this role, I am committed to helping SteadyMed engage with, and address the needs of these patients who may one day benefit from Trevyent, if approved, by the Food and Drug Administration (FDA).”

Mr. Hicks’ addition to the SteadyMed team is well aligned with the launch of our recent BePHenomenal campaign. In November, SteadyMed launched a new website, BePhenomenal.com, that is dedicated to educating and empowering people living with PH so that they can live their healthiest and most PHenomenal lives. BePhenomenal.com will offer expert lifestyle information customized for people within the PH community.

About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed on November 14, 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Contact: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com

Source: SteadyMed Therapeutics